查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984037

真菌感染疾病診斷市場：依診斷技術、病原體類型、檢體類型、感染疾病類型、檢測模式和最終用戶分類－2026-2032年全球市場預測

Fungal Infections Diagnosis Market by Diagnostic Technology, Pathogen Type, Specimen Type, Infection Type, Testing Mode, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，真菌感染疾病診斷市場價值將達到 98.4 億美元，到 2026 年將成長至 105.2 億美元，到 2032 年將達到 158.5 億美元，複合年成長率為 7.04%。

主要市場統計數據
基準年 2025 98.4億美元
預計年份：2026年 105.2億美元
預測年份：2032年 158.5億美元
複合年成長率 (%) 7.04%

現代真菌感染疾病診斷概論：臨床負擔、診斷挑戰以及對更快更準確檢測的需求

真菌感染疾病的臨床和診療緊迫性，因其在各種醫療環境中診斷的複雜性而更加凸顯。臨床醫生面臨的持續挑戰是，真菌感染疾病的症狀通常與細菌和病毒感染相似，但所需的治療策略卻截然不同。診斷的延誤和不準確會直接導致患者預後不良、住院時間延長以及抗生素抗藥性風險增加，所有這些都凸顯了更快、更準確診斷的重要性。

分子醫學、蛋白質體學、自動化、照護現場技術的進步以及數據驅動的臨床整合，推動了真菌感染疾病診斷領域的變革性變化。

隨著技術、營運和資料中心要素的融合，真菌感染疾病診斷領域正經歷變革性的轉變。分子診斷加速了從表現型鑑定到基因型和序列表徵的轉變，不僅能夠快速檢測病原體，還能提供更豐富的抗藥性決定因素和菌株層級突變資訊。同時，MALDI-TOF MS等質譜技術透過縮短鑑定時間和減少技術人員的工作時間，重新定義了檢查室工作流程。此外，顯微鏡和培養工作流程的改進也持續提供重要的確診和藥敏試驗數據。

評估 2025 年美國關稅對全球真菌感染疾病診斷供應鏈、採購經濟和創新軌蹟的累積影響。

關稅等政策會對整個診斷供應鏈、採購流程和創新生態系統產生廣泛且有時被低估的連鎖反應。 2025年，美國對某些進口商品徵收的關稅影響了真菌檢測流程中必不可少的診斷設備、耗材和試劑的成本結構。對於依賴全球供應商網路的臨床檢查室和醫院系統而言，不斷上漲的進口成本正在影響其採購決策，並加速其供應商關係多元化的進程。

為了指導策略優先排序，我們將診斷技術、最終用戶、檢體類型、病原體概況和測試模式等關鍵細分見解整合起來。

了解市場需要對診斷技術進行詳細分析，並了解每種方法如何滿足臨床應用需求和檢查室操作。基於培養的方法仍然是許多檢查室的臨床基礎，液體和固體培養基培養可透過生長和抗真菌藥物敏感性試驗提供確診機會。免疫檢測，包括酵素連結免疫吸附試驗 (ELISA) 平台和橫向流動化驗，能夠檢測抗原和抗體，支持快速臨床分流和監測，尤其是在資源有限的環境和照護現場(POC) 環境中。基質輔助雷射解吸電離飛行時間質譜 (MALDI-TOF MS) 可顯著減少鑑定培養分離株所需的時間和精力，從而加快後續臨床決策。顯微鏡檢查在許多醫療機構中仍然是快速初步診斷的關鍵，尤其是在形態學觀察可立即用於選擇適當治療方法的情況下。分子診斷包括次世代定序 (NGS) 和聚合酵素鏈鎖反應(PCR) 方法。在新一代定序（NGS）領域，Illumina和Ion Torrent定序技術在讀取準確性、通量和執行時間方面各有優勢，能夠實現全面的病原體分析和集體爆發分析。在聚合酵素鏈鎖反應（PCR）領域，傳統PCR和即時聚合酵素鏈鎖反應能夠在既定的臨床工作流程中實現標靶和高靈敏度的檢測。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和競爭格局：重點關注採用、監管和容量趨勢。

區域趨勢既影響技術採納的速度，也影響診斷服務所提供的結構。在美洲，高通量參考實驗室和綜合醫療保健系統推動了對高通量平台和整合工作流程的需求，而強大的臨床研究網路則支援定序和質譜檢驗管道的建立和早期應用。然而，複雜的報銷機制和區域採購模式要求必須清楚證明其臨床效用和成本效益，才能支持其在三級醫療機構以外的廣泛應用。

影響真菌感染疾病診斷生態系統的主要企業的企業趨勢和策略，包括創新途徑、夥伴關係和商業化策略。

競爭格局由成熟的儀器和試劑製造商、專業的分子診斷和測序平台提供者、合約研究組織 (CRO) 以及新興的軟體數據分析公司組成。市場領導者透過整合強大的儀器平台、檢驗的耗材、軟體驅動的工作流程最佳化以及能夠減輕客戶檢驗負擔的服務合約來脫穎而出。中型公司通常透過針對特定檢測領域、照護現場配置或針對特定檢查室領域量身定做的具成本效益耗材模式來與之競爭。

為產業領導者提供切實可行的建議，以加速臨床部署、加強供應鏈、最佳化產品組合，並在整個診斷領域中獲得價值。

產業領導者應優先採取一系列策略措施，在控制營運風險的同時，加速臨床應用。首先，投資進行有針對性的臨床效用研究，將診斷結果與可操作的治療決策和可衡量的患者療效聯繫起來。強而有力的臨床證據能夠降低支付方的抵觸情緒，並推動更廣泛的應用。其次，實現供應鏈多元化，考慮區域性生產和策略性庫存緩衝，以降低關稅和物流風險，並確保即使在政策變更期間也能持續提供檢測服務。

調查方法，包括一級和二級調查方法、資料檢驗、檢驗通訊協定以及分析的根本限制。

本分析採用混合研究方法，將一手質性檢驗與二手證據的系統性回顧和三角驗證結合。一手研究包括對臨床實驗室技術人員、醫院採購經理、研究機構研究人員和行業高管進行結構化訪談，以收集有關工作流程、檢驗障礙和推廣促進因素的經驗性見解。二手研究包括同行評審文獻、監管指導文件、臨床實踐指南和技術白皮書，用於為一手研究結果提供背景資訊並檢驗分析假設。

為了了解真菌感染疾病診斷的演變趨勢，本書提出簡潔的結論，為臨床醫生、實驗室管理者、投資者和政策制定者提供見解。

真菌感染疾病的診斷正在經歷重大變革時期，技術創新、供應鏈重組和實證實踐的結合正在重塑臨床格局。檢查室和醫療機構面臨複雜的抉擇，必須在分析績效、營運實際情況和支付方期望之間取得平衡。隨著分子診斷和蛋白質組學平台日益成熟，照護現場檢測（POC​​）也日益普及，那些能夠無縫整合到現有工作流程中並展現出切實臨床療效的解決方案更有可能獲得成功。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：真菌感染疾病診斷市場：依診斷技術分類

  • 培養方法
    • 液體培養基
    • 固體培養基培養
  • 免疫檢測
    • ELISA
    • 橫向流動化驗
  • MALDI-TOF-MS
  • 顯微鏡檢查
  • 分子診斷
    • 下一代定序
      • Illumina定序
      • 離子洪流序列
    • 聚合酵素鏈鎖反應
      • 常規聚合酵素鏈鎖反應
      • 即時聚合酵素鏈鎖反應

第9章：真菌感染疾病診斷市場：依病原體類型分類

  • 麴菌症
  • 念珠菌症
  • 隱球菌病
  • 皮膚絲狀菌症
  • 白黴菌症

第10章：黴菌感染疾病診斷市場：依檢體類型分類

  • 血
  • 腦脊髓液
  • 痰
  • 組織
  • 尿

第11章：真菌感染疾病診斷市場：按感染類型分類

  • 表層真菌病
  • 皮下真菌病
  • 侵襲性真菌病
  • 機會性真菌病
  • 地方性真菌病

第12章：真菌感染疾病診斷市場：依檢測模式分類

  • 臨床試驗
  • 就地檢驗
  • 僅供研究使用

第13章：真菌感染疾病診斷市場：依最終用戶分類

  • 診斷實驗室
  • 醫院和診所
  • 研究機構

第14章：真菌感染疾病診斷市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：真菌感染疾病診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：真菌感染疾病診斷市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國真菌感染疾病診斷市場

第18章：中國真菌感染疾病診斷市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amgen Inc.
  • Associates of Cape COD, Inc. by Seikagaku Group company
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioMerieux SA
  • Bruker Corporation
  • Danaher Corporation
  • DiaSorin SpA
  • Eurofins Viracor, LLC
  • F. Hoffmann-La Roche AG
  • FUJIFILM Wako Pure Chemical Corporation
  • Genobio Pharmaceutical Co., Ltd.
  • Hologic, Inc.
  • IMMY
  • InBios International, Inc.
  • Labcorp Holdings Inc.
  • Merck KGaA
  • MicroGen Diagnostics, LLC+
  • MiraVista Diagnostics, LLC
  • Norgen BIoTek Corp.
  • PathoNostics BV
  • Polysciences, Inc.
  • Qiagen NV
  • Revvity, Inc.
  • Seegene Inc.
  • Siemens Healthineers
  • T2 Biosystems, Inc.
  • Thermo Fisher Scientific Inc.
  • Xiamen Bioendo Technology Co., Ltd.
  • Zhuhai DL BIoTech Co., Ltd.
Product Code: MRR-346757DFA1E9

The Fungal Infections Diagnosis Market was valued at USD 9.84 billion in 2025 and is projected to grow to USD 10.52 billion in 2026, with a CAGR of 7.04%, reaching USD 15.85 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.84 billion
Estimated Year [2026] USD 10.52 billion
Forecast Year [2032] USD 15.85 billion
CAGR (%) 7.04%

Comprehensive introduction to contemporary fungal diagnostics, framing clinical burdens, diagnostic gaps, and the imperative for faster, more precise detection

The clinical and operational urgency around fungal infections has intensified as these pathogens continue to present diagnostic complexity across diverse care settings. Clinicians face a persistent challenge: fungal disease often mimics bacterial and viral syndromes while requiring fundamentally different therapeutic strategies. Delays or inaccuracies in diagnosis translate directly into adverse patient outcomes, extended hospital stays, and amplified antimicrobial resistance risks, which together raise the stakes for faster and more precise diagnostics.

Against this backdrop, diagnostic stakeholders are navigating a rapidly evolving toolkit that spans traditional culture methods to advanced molecular and proteomic platforms. Laboratories and hospitals are balancing the reliability of culture-based approaches with the speed advantages of molecular diagnostics and the throughput benefits of mass spectrometry technologies. At the same time, point-of-care testing is emerging as a complement to centralized workflows, particularly in outpatient and resource-limited environments where rapid decision-making is critical.

As diagnostic technologies diversify, decision-makers must weigh analytical performance, clinical utility, throughput, and cost within constrained budgets and complex reimbursement landscapes. Clinical laboratories, research institutes, and hospital networks are therefore prioritizing adoption pathways that align with institutional capabilities and patient populations. This introduction frames the subsequent analysis by highlighting the clinical imperatives, technology trade-offs, and operational considerations that will shape near-term investment and policy choices in fungal diagnostics.

Transformative shifts in fungal diagnostic landscape driven by molecular advances, proteomics, automation, point-of-care evolution, and data-driven clinical integration

The landscape of fungal diagnostics is undergoing transformative shifts driven by converging technological, operational, and data-centric forces. Molecular diagnostics have accelerated the move from phenotype-based identification toward genotypic and sequence-based characterization, enabling not only quicker pathogen detection but also richer information about resistance determinants and strain-level variation. Concurrently, mass spectrometry technologies such as MALDI TOF MS have redefined laboratory workflows by compressing identification timelines and reducing hands-on technician time, while improvements in microscopy and culture workflows continue to provide essential confirmatory and susceptibility data.

Beyond assay performance, automation and laboratory informatics are centralizing data flows and enabling more consistent workflows across decentralized laboratory networks. Integration of laboratory information systems with clinical decision support is improving result interpretation and driving more actionable reporting, thereby shortening the time from detection to therapy optimization. In parallel, the maturation of point-of-care modalities and lateral flow immunoassays is expanding diagnostic reach into outpatient clinics and emergency departments, where immediate results can drive timely antifungal stewardship decisions.

Advances in sequencing, particularly in Next Generation Sequencing methodologies, are unlocking new capabilities for comprehensive pathogen profiling and outbreak investigation. Improvements in NGS chemistry, platform accessibility, and bioinformatics pipelines are making deep sequencing feasible for diagnostic laboratories seeking to characterize complex infections or mixed populations. At the same time, real-time PCR and conventional PCR remain indispensable for targeted, rapid detection when clinical questions are narrow and turnaround time is critical.

Finally, the integration of digital health tools and artificial intelligence into fungal diagnostics is beginning to influence image-based interpretation, predictive risk stratification, and workflow optimization. Together, these shifts are not incremental; they represent a reconfiguration of diagnostic pathways, where speed, specificity, and integrated data outputs will increasingly determine clinical adoption and laboratory investment priorities.

Assessing the cumulative impact of United States tariffs in 2025 on global fungal diagnostics supply chains, procurement economics, and innovation trajectories

Policy instruments such as tariffs can have broad and sometimes underappreciated ripple effects across diagnostic supply chains, procurement practices, and innovation ecosystems. In 2025, United States tariffs introduced on selected imports are influencing cost structures for diagnostic instruments, consumables, and reagents that are integral to fungal testing workflows. For clinical laboratories and hospital systems that rely on global supplier networks, incremental import costs are shaping purchasing decisions and accelerating efforts to diversify vendor relationships.

Procurement teams are responding by recalibrating supplier mixes, increasing order consolidation where possible, and exploring domestic manufacturers for critical components to mitigate exposure to tariff-driven price volatility. These adaptations carry operational implications: validated alternative suppliers require requalification, and product substitutions can affect workflow efficiency and diagnostic continuity. In research settings, higher reagent costs are complicating study design and budget planning, which in turn can slow translational research efforts and delay the generation of clinical validation data that underpins adoption.

Tariffs are also influencing innovation strategies among manufacturers. Some vendors are reshaping supply chains through near-shoring and localized manufacturing investments to preserve competitive pricing while maintaining product availability. Others are accelerating product portfolios toward consumable-efficient platforms or integrated systems that reduce dependency on high-tariff components. From a market perspective, these shifts may alter the pace at which laboratories upgrade to next-generation platforms, and they may reshape negotiations between customers and suppliers around volume-based pricing and multi-year service agreements.

Importantly, regulatory and reimbursement frameworks interact with tariff impacts. Healthcare payers and hospitals may be slower to approve higher-cost diagnostics absent clear evidence of improved clinical outcomes, which places a premium on robust clinical utility studies. In summary, tariffs are prompting a multi-dimensional response that spans procurement, validation, manufacturing strategy, and evidence generation, and stakeholders that proactively adapt their supply chain and clinical evidence strategies will be better positioned to sustain service quality and innovation momentum.

Key segmentation insights synthesizing diagnostic technologies, end users, specimen types, pathogen profiles, and testing modes to guide strategic prioritization

Understanding the market requires a granular view of diagnostic technologies and how each modality maps to clinical use cases and laboratory operations. Culture Based approaches remain the clinical backbone for many laboratories, with liquid broth culture and solid media culture providing growth-based confirmation and the opportunity for antifungal susceptibility testing. Immunoassays, including Elisa platforms and lateral flow assay formats, deliver antigen and antibody detection that supports rapid clinical triage and surveillance, particularly in resource-constrained or point-of-care settings. MALDI TOF MS has materially lowered time-to-identification for cultured isolates, reducing labor and accelerating downstream clinical decision-making. Microscopy continues to be indispensable for rapid presumptive diagnosis in many care environments, particularly when morphology informs immediate therapeutic choices. Molecular Diagnostics encompass both Next Generation Sequencing and Polymerase Chain Reaction based approaches. Within NGS, Illumina Sequencing and Ion Torrent Sequencing offer complementary trade-offs between read accuracy, throughput, and run time, enabling comprehensive pathogen profiling and outbreak analytics. Within PCR, Conventional Polymerase Chain Reaction and Real Time Polymerase Chain Reaction provide targeted, highly sensitive detection with well-established clinical workflows.

End users include Diagnostic Laboratories, Hospitals & Clinics, and Research Institutes, each with distinct drivers for technology adoption and investment. Diagnostic laboratories prioritize platforms that balance throughput, cost-per-test, and integration with laboratory information systems, while hospitals and clinics often favor rapid-turnaround modalities that can directly influence patient management. Research institutes focus on depth of characterization and flexibility for exploratory assays, often serving as early adopters for advanced sequencing and proteomic methods.

Specimen types such as blood, cerebrospinal fluid, sputum, tissue, and urine frame analytical requirements and pre-analytical workflows. Blood and cerebrospinal fluid demand assays with high analytical sensitivity and contamination control given the clinical severity of bloodstream and central nervous system infections. Respiratory specimens like sputum and tissue samples introduce complexity in sample processing and often benefit from combined culture and molecular workflows. Urine-based testing, while less common for invasive disease, is valuable in certain surveillance and outpatient contexts.

Pathogen-type segmentation-including Aspergillosis, Candidiasis, Cryptococcosis, Dermatophytosis, and Mucormycosis-drives diagnostic target selection, as each genus and clinical syndrome has different analytic challenges, resistance profiles, and specimen preferences. Testing modes span Laboratory Testing, Point Of Care Testing, and Research Use Only applications, reflecting the spectrum from clinically actionable diagnostics to exploratory and investigational assays. Taken together, these segmentation dimensions inform strategic prioritization for technology development, regulatory planning, and commercialization pathways, as trade-offs between sensitivity, speed, and operational fit differ across each segment and user class.

Regional dynamics and competitive positioning across the Americas, Europe, Middle East & Africa, and Asia-Pacific highlighting adoption, regulation, and capacity trends

Regional dynamics shape both the pace of technology adoption and the structure of diagnostic service delivery. In the Americas, high-capacity reference laboratories and integrated health systems drive demand for high-throughput platforms and consolidated workflows, while strong clinical research networks support pathway validation and early adoption of sequencing and mass spectrometry. Reimbursement complexity and regional procurement models, however, require clear demonstration of clinical utility and cost-effectiveness to support widespread deployment beyond tertiary centers.

In Europe, Middle East & Africa, heterogeneity in healthcare infrastructure results in a dual market pattern: advanced laboratories in urban centers and tertiary hospitals adopt cutting-edge molecular and proteomic platforms, while many settings continue to rely on robust culture and immunoassay workflows. Regulatory harmonization efforts in parts of Europe facilitate cross-border adoption, but diverse reimbursement landscapes and variable laboratory capacity in the broader region necessitate adaptable product designs and targeted implementation support.

In Asia-Pacific, rapid investments in laboratory capacity and a growing focus on infectious disease preparedness are creating fertile conditions for both centralized and decentralized diagnostics. Market dynamics in this region are influenced by a mix of large public health procurements and private sector laboratory expansion, offering opportunities for manufacturers that can scale supply and provide training and validation support. Across all regions, local manufacturing, supply chain resilience, and regulatory alignment are increasingly decisive factors that affect procurement cycles and the speed at which new technologies are integrated into routine practice.

Corporate intelligence and key company strategies shaping the fungal diagnostics ecosystem including innovation pathways, partnerships, and commercialization playbooks

The competitive landscape is characterized by a mix of established instrument and reagent manufacturers, specialized molecular and sequencing platform providers, contract research organizations, and emergent software and data analytics firms. Market leaders are differentiating through integrated solutions that combine robust instrument platforms with validated consumables, software-enabled workflow orchestration, and service agreements that reduce customer validation burdens. Mid-tier players often compete on niche assays, point-of-care formats, or cost-effective consumable models that fit specific laboratory segments.

Strategic collaborations and distribution partnerships are common, enabling companies to extend geographic reach and couple complementary technologies-such as linking a mass spectrometry identification system with a molecular resistance assay. Additionally, start-ups are introducing focused innovations in areas such as simplified sample preparation, rapid lateral flow formats with enhanced sensitivity, and bioinformatics tools that streamline NGS interpretation. Contract laboratories and reference testing networks play a pivotal role as early adopters and validators, providing pathways for new technologies to demonstrate clinical utility and drive broader laboratory adoption.

A clear pattern emerges where companies that invest in evidence generation, regulatory preparedness, and scalable service models are better positioned to secure long-term contracts with health systems. Moreover, firms that can offer training, remote support, and integration with laboratory information systems reduce friction for customers and accelerate uptake. Competitive advantage increasingly hinges on the ability to deliver end-to-end solutions that address analytical performance, operational efficiency, and the practical realities of laboratory validation and clinician adoption.

Actionable recommendations for industry leaders to accelerate clinical adoption, fortify supply chains, optimize portfolios, and capture value across diagnostic segments

Industry leaders should prioritize a set of strategic actions that accelerate clinical adoption while managing operational risks. First, invest in targeted clinical utility studies that link diagnostic outputs to actionable treatment decisions and measurable patient outcomes; robust clinical evidence reduces payer resistance and supports broader uptake. Second, diversify supply chains and consider regional manufacturing or strategic inventory buffering to mitigate tariff and logistics risks, ensuring continuity of testing services during policy-driven disruptions.

Third, align product development with end-user workflows by offering modular platforms that support both high-throughput centralized testing and rapid point-of-care use cases. This approach increases addressable use cases while allowing laboratories to scale adoption according to capacity. Fourth, strengthen partnerships with reference laboratories and clinical networks to facilitate third-party validation, early use-case documentation, and clinician education that can accelerate adoption curves. Fifth, embed software-driven value propositions-such as connectivity, result interpretation, and workflow automation-into offerings to reduce laboratory burden and improve result utility for clinicians.

Finally, engage proactively with regulatory bodies and payers to clarify evidence expectations and reimbursement pathways early in development. By anticipating regulatory and reimbursement questions and incorporating real-world evidence collection into rollouts, companies can shorten time-to-market and reduce adoption friction. These actions, taken together, create a resilient commercial strategy that balances innovation, evidence generation, and operational continuity.

Transparent research methodology outlining primary and secondary research approaches, data triangulation, validation protocols, and limitations informing the analysis

The analysis is founded on a mixed-methods research approach that integrates primary qualitative inquiry with systematic secondary evidence review and triangulation. Primary research included structured interviews with clinical laboratorians, hospital procurement leaders, research institute investigators, and industry executives to capture experiential insights into workflows, validation barriers, and adoption drivers. Secondary research encompassed peer-reviewed literature, regulatory guidance documents, clinical practice guidelines, and technology white papers to contextualize primary findings and to verify analytical assumptions.

Data triangulation was employed to reconcile disparate inputs and to identify consistent patterns across stakeholder groups and evidence sources. Technology mapping and capability assessments were performed to align platform characteristics with clinical use cases and laboratory operational constraints. Additionally, a review of clinical trial registries and patent filings informed the forward-looking view on innovation trajectories and emerging assay modalities.

The research recognizes limitations inherent to qualitative and secondary data, including variability in regional reporting, evolving regulatory landscapes, and the lag between technological development and published clinical validation. To mitigate these limitations, the analysis emphasizes corroborated themes and distinguishes between observed practice and aspirational capabilities. Where appropriate, sensitivity to regional heterogeneity and institutional capacity has been maintained to ensure that recommendations are actionable across diverse healthcare contexts.

Concise conclusion synthesizing implications for clinicians, laboratory leaders, investors, and policymakers to navigate the evolving fungal diagnostics landscape

Fungal diagnostics are in a period of substantive evolution where technological innovation, supply chain realignment, and evidence-driven adoption converge to reshape clinical practice. Laboratories and healthcare organizations face a complex landscape of choices that must balance analytical performance with operational realities and payer expectations. As molecular and proteomic platforms mature and point-of-care modalities broaden access, success will favor solutions that demonstrate tangible clinical impact while integrating smoothly into existing workflows.

Policy and procurement variables, such as tariffs and regional manufacturing dynamics, will continue to influence investment and adoption patterns. Stakeholders that proactively address these factors through diversified sourcing, strategic partnerships, and focused evidence generation will preserve continuity of diagnostic services and accelerate innovation uptake. Ultimately, sustained progress will depend on collaborative approaches that link manufacturers, clinical leaders, and health systems in shared efforts to validate, implement, and optimize diagnostic pathways for fungal disease.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Fungal Infections Diagnosis Market, by Diagnostic Technology

  • 8.1. Culture Based
    • 8.1.1. Liquid Broth Culture
    • 8.1.2. Solid Media Culture
  • 8.2. Immunoassays
    • 8.2.1. Elisa
    • 8.2.2. Lateral Flow Assay
  • 8.3. MALDI TOF MS
  • 8.4. Microscopy
  • 8.5. Molecular Diagnostics
    • 8.5.1. Next Generation Sequencing
      • 8.5.1.1. Illumina Sequencing
      • 8.5.1.2. Ion Torrent Sequencing
    • 8.5.2. Polymerase Chain Reaction
      • 8.5.2.1. Conventional Polymerase Chain Reaction
      • 8.5.2.2. Real Time Polymerase Chain Reaction

9. Fungal Infections Diagnosis Market, by Pathogen Type

  • 9.1. Aspergillosis
  • 9.2. Candidiasis
  • 9.3. Cryptococcosis
  • 9.4. Dermatophytosis
  • 9.5. Mucormycosis

10. Fungal Infections Diagnosis Market, by Specimen Type

  • 10.1. Blood
  • 10.2. Cerebrospinal Fluid
  • 10.3. Sputum
  • 10.4. Tissue
  • 10.5. Urine

11. Fungal Infections Diagnosis Market, by Infection Type

  • 11.1. Superficial Mycoses
  • 11.2. Subcutaneous Mycoses
  • 11.3. Invasive Mycoses
  • 11.4. Opportunistic Mycoses
  • 11.5. Endemic Mycoses

12. Fungal Infections Diagnosis Market, by Testing Mode

  • 12.1. Laboratory Testing
  • 12.2. Point Of Care Testing
  • 12.3. Research Use Only

13. Fungal Infections Diagnosis Market, by End User

  • 13.1. Diagnostic Laboratories
  • 13.2. Hospitals & Clinics
  • 13.3. Research Institutes

14. Fungal Infections Diagnosis Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Fungal Infections Diagnosis Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Fungal Infections Diagnosis Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Fungal Infections Diagnosis Market

18. China Fungal Infections Diagnosis Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Amgen Inc.
  • 19.6. Associates of Cape COD, Inc. by Seikagaku Group company
  • 19.7. Becton, Dickinson and Company
  • 19.8. Bio-Rad Laboratories, Inc.
  • 19.9. BioMerieux SA
  • 19.10. Bruker Corporation
  • 19.11. Danaher Corporation
  • 19.12. DiaSorin S.p.A.
  • 19.13. Eurofins Viracor, LLC
  • 19.14. F. Hoffmann-La Roche AG
  • 19.15. FUJIFILM Wako Pure Chemical Corporation
  • 19.16. Genobio Pharmaceutical Co., Ltd.
  • 19.17. Hologic, Inc.
  • 19.18. IMMY
  • 19.19. InBios International, Inc.
  • 19.20. Labcorp Holdings Inc.,
  • 19.21. Merck KGaA
  • 19.22. MicroGen Diagnostics, LLC+
  • 19.23. MiraVista Diagnostics, LLC
  • 19.24. Norgen Biotek Corp.
  • 19.25. PathoNostics B.V.
  • 19.26. Polysciences, Inc.
  • 19.27. Qiagen N.V.
  • 19.28. Revvity, Inc.
  • 19.29. Seegene Inc.
  • 19.30. Siemens Healthineers
  • 19.31. T2 Biosystems, Inc.
  • 19.32. Thermo Fisher Scientific Inc.
  • 19.33. Xiamen Bioendo Technology Co., Ltd.
  • 19.34. Zhuhai DL Biotech Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LIQUID BROTH CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LIQUID BROTH CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LIQUID BROTH CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SOLID MEDIA CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SOLID MEDIA CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SOLID MEDIA CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MALDI TOF MS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MALDI TOF MS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MALDI TOF MS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ILLUMINA SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ILLUMINA SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ILLUMINA SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ION TORRENT SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ION TORRENT SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ION TORRENT SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ASPERGILLOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ASPERGILLOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ASPERGILLOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CANDIDIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CANDIDIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CANDIDIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CRYPTOCOCCOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CRYPTOCOCCOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CRYPTOCOCCOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DERMATOPHYTOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DERMATOPHYTOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DERMATOPHYTOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MUCORMYCOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MUCORMYCOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MUCORMYCOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CEREBROSPINAL FLUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CEREBROSPINAL FLUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CEREBROSPINAL FLUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPUTUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPUTUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPUTUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUPERFICIAL MYCOSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUPERFICIAL MYCOSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUPERFICIAL MYCOSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUBCUTANEOUS MYCOSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUBCUTANEOUS MYCOSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUBCUTANEOUS MYCOSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INVASIVE MYCOSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INVASIVE MYCOSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INVASIVE MYCOSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY OPPORTUNISTIC MYCOSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY OPPORTUNISTIC MYCOSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY OPPORTUNISTIC MYCOSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ENDEMIC MYCOSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ENDEMIC MYCOSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ENDEMIC MYCOSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LABORATORY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LABORATORY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH USE ONLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH USE ONLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH USE ONLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. GCC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. GCC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. GCC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 234. GCC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 235. GCC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 236. GCC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 237. GCC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 238. GCC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. GCC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. GCC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. GCC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 242. GCC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. G7 FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. G7 FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. G7 FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 270. G7 FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 271. G7 FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 272. G7 FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 273. G7 FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 274. G7 FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. G7 FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. G7 FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. G7 FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 278. G7 FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 279. NATO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. NATO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 281. NATO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 282. NATO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 283. NATO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 284. NATO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 285. NATO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 286. NATO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. NATO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. NATO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. NATO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 290. NATO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES FU